MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, RLMD has $94,003,471 in assets. $7,491,458 in debts. $3,496,540 in cash and cash equivalents.

Balance Sheets Overview

Current Ratio
1461.53%
Quick Ratio
1461.53%
Cash Ratio
54.37%
Debt to Asset Ratio
7.97%
Unit: Dollar
Assets Breakdown
    • Short-term investments
    • Cash and cash equivalents
    • Prepaid expenses
    • Other assets
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Accrued expenses
    • Others

Balance Sheets
2025-12-31
Cash and cash equivalents
3,496,540
Short-term investments
89,509,710
Prepaid expenses
977,721
Total current assets
93,983,971
Other assets
19,500
Total assets
94,003,471
Accounts payable
1,568,944
Accrued expenses
4,861,583
Total current liabilities
6,430,527
Stock appreciation rights
1,060,931
Total liabilities
7,491,458
Common stock, 0.001 par value, 150,000,000 shares authorized, 73,333,622 and 30,174,202 shares issued and outstanding, respectively
73,333
Additional paid-in capital
784,705,878
Accumulated deficit
-698,267,198
Total stockholders equity
86,512,013
Total liabilities and stockholders equity
94,003,471
Unit: Dollar.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Short-term investments$89,509,710 Cash and cashequivalents$3,496,540 Prepaid expenses$977,721 Total current assets$93,983,971 Other assets$19,500 Total assets$94,003,471 Total liabilities andstockholders equity$94,003,471 Total stockholdersequity$86,512,013 Total liabilities$7,491,458 Accumulated deficit-$698,267,198 Additional paid-in capital$784,705,878 Total currentliabilities$6,430,527 Stock appreciationrights$1,060,931 Common stock, 0.001 parvalue, 150,000,000...$73,333 Accrued expenses$4,861,583 Accounts payable$1,568,944

RELMADA THERAPEUTICS, INC. (RLMD)

RELMADA THERAPEUTICS, INC. (RLMD)